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Background: Liver disease is an important cause of death in adults with cystic fibrosis (CF). Ursodeoxycholic acid (UDCA) may slow
progression. Managing varices and timely evaluation for liver transplantation are important.
Methods: Adults with CF underwent annual review. Abnormalities of liver function tests or ultrasound prompted referral to the CF/liver clinic
where UDCA was commenced. Endoscopic surveillance for varices was undertaken if ultrasound suggested portal hypertension.
Results: 154 patients were followed for a median 5 years. 43 had significant liver disease, 29 had cirrhosis with portal hypertension and 14 had
ultrasound evidence of cirrhosis without portal hypertension. All started UDCA. Only one patient developed chronic liver failure and none
required liver transplantation. 27 underwent endoscopy; 1 required variceal banding, the others had insignificant varices. Ultrasound was normal
in 97 patients while five had steatosis; nine further patients had splenomegaly but no other evidence of portal hypertension. Neither spleen size nor
platelet count correlated with portal hypertension.
Conclusions: Liver disease was common in adults with CF but disease progression was rare. Thus liver disease detected and closely monitored in
adults appeared to have a milder course than childhood CF. Splenomegaly, unrelated to portal hypertension may be a consequence of CF.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Liver disease; Ursodeoxycholic acid; Portal hypertension; Endoscopy1. Introduction
Cystic fibrosis (CF) is the commonest life threatening
genetic disorder in Caucasians [1]. Advances in the manage-
ment of pulmonary complications, the evolution of multi-
disciplinary teams and improved nutrition have extended life
expectancy [2]. However, increased survival has emphasised
the importance of liver disease, which is now the third leading
cause of death for adults with CF [3–5].⁎ Corresponding author. Department of Medicine, Box 210, Addenbrooke's
Hospital, Hills Road, Cambridge. CB2 2QQ, USA. Tel.: +1 44 1223 245151;
fax: +1 44 1223 216111.
E-mail address: kathryn.nash@addenbrookes.nhs.uk (K.L. Nash).
1569-1993/$ - see front matter © 2007 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2007.10.004The prevalence of liver disease among patients with CF
ranges from 2% to 37%, depending on the definition [6, 7]. Liver
function tests and other serum markers lack specificity and
sensitivity as predictors of liver disease in patients with CF [8–
11]. Histological assessment, the gold-standard for the diagnosis
of many chronic liver disorders, is of questionable value in CF
due to the focal nature of the disease [4]. Ultrasound examination
has been evaluated retrospectively and prospectively and is a
useful marker of early liver disease and progressive liver injury
[12–14]. However, ultrasound is operator dependent and may
over estimate the severity of liver disease, since some
abnormalities detected may be the consequence of infection,
malnutrition or venous congestion rather than chronic liver
disease.d by Elsevier B.V. All rights reserved.
Table 1
The classification of patients according to ultrasound criteria
Classification Ultrasound features
Cirrhosis/severe
fibrosis
Heterogeneous liver echo texture (either coarse or reduced
echo reflectivity) Nodular/lobular/irregular liver margin Left
lobe hypertrophy No features of portal hypertension
Portal
hypertension
Presence of intra-abdominal varices Enlargement of splenic
hilar vessels Re-canalised umbilical vein Dilated/prominent
portal vein Altered portal venous Doppler flow (turbulent,
equilibrated or reversed)
Steatosis Bright echo texture Reduced penetration of ultrasound
Smooth liver margin No evidence of portal hypertension
Splenomegaly Spleen N12 cm No other evidence of portal hypertension No
abnormalities of liver
Patients were considered to have cirrhosis if they had a heterogeneous echo
texture and an irregular liver margin. Patients were considered to have
ultrasound evidence of portal hypertension if they had any of the features listed.
(The normal range for spleen size was defined as 9–11 cm. This may be an over
estimate in this population as the majority of patients are of small stature).
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ment of CF-related liver disease is unproven. The beneficial
effects of UDCA in improving liver function tests in other
cholestatic disorders, including primary biliary cirrhosis, are
well described [15,16]. UDCA has been shown to improve liver
function tests and liver histology in prospective studies of
patients with CF [17,18], although a Cochrane review found
insufficient evidence to justify the routine use of UDCA [19].
Despite this, many groups continue to use UDCA in patients
with CF and report benefit [20].
The majority of patients with CF-related liver disease present
in their first decade. The incidence and progression of liver
disease in the paediatric population are well described [21–23]
and liver transplantation is an established therapy for end-stage
liver disease in children with CF [24].
Few studies have addressed the prevalence and natural
history of liver disease in adults with CF, so the impact of liver
disease on patients surviving into adulthood is uncertain. In
addition, adults with CF and chronic liver failure are more likely
to have cardio-respiratory disease precluding liver transplanta-
tion alone and are more likely to need multi-organ transplanta-
tion. An audit at this centre indicated that patients with CF
undergoing simultaneous heart, lung and liver transplantation
had a poor outcome [25] as reported by others [26].
The combined Cambridge/Papworth adult CF/liver clinic was
established with three aims: [1] to identify patients with CF at risk
of progressive liver injury [2] to optimise management of liver
disease and [3] to balance the likely needs of each patient with
chronic respiratory or liver failure with regard to the timing of
organ replacement. This study is a prospective audit of that service.
2. Materials and methods
Adults (N16-years) attending the adult CF centre at Papworth
Hospital undergo annual review including clinical examination,
serum liver function tests and an abdominal ultrasound (US)
performed by a non-specialist radiologist. Abnormal clinical
findings, or abnormalities of liver function tests (above upper
limit of normal) or ultrasound prompt referral to the joint adult
CF/liver clinic at Addenbrooke's Hospital, Cambridge, which is
manned by a hepatologist (GA), a physician with an interest in
CF (CH or DB) and a radiologist with a particular interest in the
liver (DL). The assessment pathway is such that any abnormality
in the liver evaluation leads to referral to the specialist clinic. In
this way, no patient with liver disease is overlooked but many
patients are screened who are subsequently found to have no
liver disease at specialist review. Additionally, patients present-
ing with symptoms or signs of liver disease at any other time are
also referred to the CF/liver clinic.
Assessment at the specialist clinic includes history (including
alcohol consumption), clinical examination, tests for concomitant
causes of chronic liver disease (for example viral hepatitis,
autoimmune liver disease, iron overload and alpha-1 antitrypsin
deficiency) and liver ultrasound by a liver radiologist (DL).
Patients were prescribed UDCA (target dose 15 mg/Kg) and
monitored 6-monthly if abnormalities were confirmed after
specialist liver US. Specialist liver US, alongside clinicalassessment, allowed classification of patients into groups
(Table 1). The texture of the liver could not be determined
definitively by liver US in a minority of cases and these patients
had further imaging with magnetic resonance (MRI). If the liver
ultrasound suggested cirrhosis, 6-monthly ultrasound and serum
α-foetoprotein were performed to screen for hepatocellular car-
cinoma. In addition, patients with ultrasound characteristics of
cirrhosis with features of portal hypertension underwent endo-
scopic surveillance for varices annually. The respiratory physician
reviewed patients prior to endoscopy in order to optimise their
condition with antibiotics and physiotherapy as required. A single
operator with experience in assessment andmanagement of portal
hypertension undertook all endoscopy (MA).
The data were obtained by prospective analysis of all patients
referred to the service between 1995 and 2006. Patients were
included if follow up exceeded 2 years.
3. Results
154 patients were followed for a median of 5 years (range 2–
10). Any abnormality of liver assessment (history, clinical
findings, laboratory test or screening US) was utilised to guide
referral. Specialist liver ultrasound allowed classification of
patients into groups (Table 2). 43 (28%) had US evidence of
cirrhosis (Table 2).
29 (19%) patients had an ultrasound diagnosis of cirrhosis with
portal hypertension that had been underestimated prior to referral
to the specialist clinic. All were commenced on therapy with
UDCA. One patient developed progressive liver failure and
ultimately succumbed to an acute respiratory arrest. Her case was
complicated by cholelithiasis, concomitant alcohol usage, worsen-
ing respiratory infections, pancreatitis and jaundice possibly
related to flucloxacillin. No other patient developed chronic liver
failure and none required liver transplantation (median follow up
64 months, range 24–117months). None had ultrasound evidence
of progressive portal hypertension (new varices, increasing spleen
size, alteration in portal vein size or flow) and no one under regular
follow up developed hepatocellular carcinoma (HCC); in three
patients a reduction in spleen size was documented on UDCA (18
Table 2
Classification of 155 patients with or without CF-related liver disease (based on
ultrasound findings and clinical status)
n (%) Male Mean age
at first
review
Mean BMI
at first
review
Mean FEV1
(% predicted
at first review)
Cirrhosis with
portal hypertension
29(19) 20 20.0 20.0 57.9
Cirrhosis/fibrosis
(without portal
hypertension)
14(9) 6 20.5 21.0 70.7
Steatosis 5(3) 4 21.5 19.6 52.0
Splenomegaly alone 9(6) 6 17.5 18.25 50.1
Normal 97(63) 60 21.8 19.7 58.2
Table 3
The relation between spleen size, platelet count and the presence or absence of
endoscopic evidence of portal hypertension⁎
Spleen
size cms
(median)
Spleen
size cms
(range)
Platelet
count ×109/L
(median)
Platelet
count ×109/L
(range)
No portal
hypertension n=15
14.3 12–16 248 89–379
PHG n= 3 15.5 15–16 278 214–378
Grade 1 varices a n= 8 16.4 10–23 146 64–363
Grade 2/3 varices b n=1 15 15 106 106
Portal
hypertension c n=12
16.2 10–23 179 64–378
PHG= Portal hypertensive gastropathy.
⁎For those who had more than one endoscopy data is given for the time of their
first endoscopy.
a small varices not requiring therapy.
b large varices in need of banding.
c Portal hypertension (any manifestation).
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flow in the portal vein was restored to normal.
Two patientswere assessed specifically for transplantation.One
was considered for liver transplantation alone but portal hyperten-
sion was insignificant; it was deemed too early for liver trans-
plantation and the patient remains well 5 years after assessment.
One patient with portal hypertension developed respiratory failure
and was considered for multi-organ transplantation. It was felt that
portal hypertension was not life threatening and that liver
transplant was not warranted, but should not preclude heart/lung
transplant, for which he was listed. Prophylactic banding of
oesophageal varices was undertaken while awaiting surgery.
Varices were eradicated and he underwent lung transplantation but
died shortly afterwards of multi-organ failure.
14 (9%) had a heterogeneous liver consistent with cirrhosis or
severe fibrosis but without portal hypertension on ultrasound and
were prescribed UDCA. One patient was intolerant of UDCA and
serial ultrasound revealed progressive disease with increased
spleen size and more marked irregularity of the liver. 13 of 14
patients tolerated UDCA; none had evidence of progressive liver
injury or HCC after a median follow up of 53 months (range 24–
96 months). 2 had ultrasound features of improvement (spleen
size reduced from 12 to 9 cm and from 12 to 10 cm).
The remaining 111 patients remained stable with regard to
the liver. None had evidence of progressive liver injury or HCC
after a median follow up 70 months (range 24–120 months).
They comprised:
• 81 with a normal specialist liver ultrasound
• 9 (6%) patients with splenomegaly on ultrasound but no
other evidence of liver disease or portal hypertension, after
careful extended follow up
• 21 were referred because of non-specialist ultrasound
evidence of periportal fibrosis. Five had a bright echo
texture observed consistent with hepatic steatosis which was
confirmed by MRI scanning. The remainder were deemed
normal by a more experienced radiologist making the total
with normal liver ultrasound 97 (63%).
3.1. Pulmonary function
Patients with cirrhosis had a mean follow up of 64 months
(range 24–117). Over this time, eight patients (28%) died ofrespiratory disease; one of these died after heart/lung trans-
plantation. No other patient with cirrhosis received a heart/lung
transplant. Overall, however, there was no significant deteriora-
tion in lung function. Baseline FEV1 fell from a mean of 57.9 to
55.0% predicted ( p=0.7).
3.2. Nutrition
During follow up patients with cirrhosis had regular nutritional
assessment. BMI rose or remained stable in all patients (mean
20.0 to 21.5) implying that in this group of stable patients on
ursodeoxycholic acid, chronic liver disease was not associated
with deteriorating nutritional state.
3.3. Endoscopy
24 of 29 cirrhotic patients underwent endoscopic surveil-
lance for portal hypertension. One patient declined and four
patients had advanced respiratory disease and it was felt that
endoscopy would be hazardous or inappropriate. Three further
patients with an uncertain ultrasound assessment underwent
precautionary endoscopy. Findings at endoscopy are shown in
Table 3.
Thirteen patients had more than one endoscopy. One patient
was enrolled into a variceal banding programme in order to
eradicate four large varices prior to heart/lung transplantation.
Varices were eradicated after four procedures (over 4 weeks)
and remained controlled until he died 2 years later following
heart/lung transplantation. One patient showed endoscopic
evidence of minor progression over a two-year follow up with
a single grade 1 varix progressing to a single grade 2 varix that
did not require treatment. Two patients improved; one had two
grade 1 varices at initial endoscopy but a normal endoscopy
with no evidence of portal hypertension after a three year follow
up; the other had regression of portal hypertensive gastropathy
at eighteen month follow up. All other patients remained stable
between endoscopies (median follow up 2.3 years).
The correlation between spleen size or platelet count and the
presence of portal hypertension was analysed in patients with
Table 4
Other liver disorders detected
Gilbert's disease 1
Alcohol related liver disease 4
Symptomatic gall stone disease 8
Benign liver lesion (haemangioma, regenerative nodules, focal fat variation) 5
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was no correlation between spleen size and the endoscopic
presence of varices. Spleen size was increased in most patients
with liver disease regardless of whether there was endoscopic
evidence of portal hypertension (Table 3). In addition, nine
other patients had splenomegaly on ultrasound without any
other evidence of portal hypertension. Only one patient with
cirrhosis had a normal spleen size. Although there was a trend
towards those with portal hypertension having a lower platelet
count than those without (Table 3) the majority of patients had a
normal platelet count.
3.4. Other liver diseases
All patients underwent a full screen for chronic liver disease
in addition to a full history and clinical examination. Table 4
shows the other diagnoses that were made as a result. Three
patients had clinical diagnoses of alcohol related liver disease
with supportive history and echo bright liver on US that
resolved upon alcohol cessation; none have developed cirrhosis.
One further patient thought to have CF liver disease gave a
history of alcohol excess. A liver biopsy performed to clarify
the diagnosis demonstrated a biliary cirrhosis secondary to CF
but with additional features of an alcohol related steatohepatitis.
One patient with CF-related cirrhosis developed focal lesions.
These were extensively evaluated with US and MRI and foundFig. 1. Analysis of (a) spleen size by ultrasound and (b) platelet count in relation
to portal hypertension. Data points represent the mean and error bars show the
range. Data are included for 12 patients who were referred from outside the
region for liver transplantation. All had marked portal hypertension and
underwent liver transplantation for this indication.to be consistent with regenerative nodules. All other abnorm-
alities were found in patients deemed not to have CF liver
disease in the specialist clinic.
4. Discussion
The poor outcome of simultaneous heart, lung and liver
transplantation for adults with CF in the combined Addenbroo-
ke's/Papworth series [25] was the major stimulus to establish the
joint CF/liver clinic. The purpose was to identify patients with
early progressive liver disease before respiratory failure deterio-
rated to a level that would preclude multi-organ or liver
transplantation. The aim was to consider early liver transplanta-
tion to allow improvement in pulmonary function as reported
[24,26] and to consider heart/lung transplantation at a later stage if
needed. The findings of this prospective study of consecutive,
unselected adults with CF were therefore surprising and striking.
With the exception of one complex case, there was no evidence of
progressive liver disease in a large cohort of patients during a
period when we continued to perform liver transplantation alone
for patients referred fromoutside our region (12 cases). No patient
followed prospectively has developed any clinical manifestation
of portal hypertension, end-stage liver disease or HCC and no
patient has needed liver transplantation. We have previously
reported a patient who underwent liver transplantation for HCC
[27], which was present at the time of referral to Cambridge from
another centre. The single patient who developed hepatic
decompensation was known to have a severely fibrotic liver but
not cirrhosis and did not have varices. Significant alcohol usage
was a co-factor. She developed sudden hepatic decompensation
associated with multiple respiratory infections and a possible
adverse reaction to flucloxacillin with jaundice. Liver transplan-
tation was not possible in the face of the rapid deterioration and
respiratory complications in this particular case.
The reason for the long-term stability in this series of adults
with CF-related liver disease is uncertain. It may reflect the
benefit of careful, single centre, multidisciplinary care with
attention to detail including appropriate and prompt treatment of
sepsis and maintained nutrition with unknown and indirect
effects on the liver. Another option is that all patients with liver
abnormalities were made aware of their situation, were
recommended treatment with UDCA and were encouraged to
continue therapy long term. Reduced spleen size and correction
of hepatofugal portal blood flow in some cases on treatment and
progressive liver disease with intolerance of UDCA might
suggest a direct effect of therapy, although small numbers
preclude statistical analysis.
A further explanation for stable liver disease is that adults with
CF have a milder phenotype with slower progression of liver
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paediatric group where it is recognised that liver disease
progresses from asymptomatic portal fibrosis to symptomatic
portal hypertension with variceal haemorrhage, ascites and liver
failure [28]. Historically, the prognosis is unfavourable once
portal hypertension is established; 20% of children die after a
mean 4.5 years [29]. It is clear from this series that progression is
not inevitable in carefully monitored adults with CF-related liver
disease. As our adult clinic was established to assess patients early
and stratify treatment before they developedmulti-organ failure, it
was not appropriate to have a “control” group who were not
monitored. Therefore we cannot determine whether the non-
progressive disease course reflected the careful clinic follow up or
the fact that the disease is non-progressive in this age group. We
did however have continued referral of adult patients for liver
transplantation from outside our centre arguing that the natural
history of the adult disorder may also be progressive.
Another explanation for the high incidence of portal hyperten-
sion without progressive disease might be that ultrasound
overestimated the degree of liver disease. Assessment of the
severity of liver disease in CF is notoriously difficult. However,
ultrasound probably represents the best available technique for
documenting liver involvement. A coarse hepatic parenchyma,
nodularity of the liver edge and increased periportal echogenicity
enable accurate, early diagnosis of liver involvement in CF [13].
This technique has high specificity (92%) but low sensitivity
(50%) for the presence of liver disease [30]. In this study, liver
ultrasound was performed in a tertiary referral liver centre with
extensive experience and was combined with clinical and
biochemical examination to enable the best possible assessment
of the presence of liver disease. Furthermore, additional
radiological investigation with MRI was utilised in cases where
US alone could not differentiate confidently between steatosis and
fibrosis. As the proportion of patients who were shown
subsequently to have endoscopic evidence of portal hypertension
(44%) is consistent with that seen in other causes of biopsy proven
cirrhosis [31–34] it is likely that our US evaluation was reliable at
determining the severity of liver disease. However, as liver biopsy
is not a gold-standard in CF liver disease due to the focal nature of
the pathology it is not possible to conclusively verify this.
Endoscopic screening for the presence of oesophageal varices
is considered routine in patients with cirrhosis. In patients with CF
this is a considerable undertaking because of limited respiratory
reserve, the requirement for sedation and the attendant risk of
aspiration. In addition, repeated endoscopy with variceal band
ligation might be required for primary prophylaxis against
variceal haemorrhage if significant varices were found, since
some CF patients may not tolerate beta-blockade due to an
“asthmatic” component to their airway disease [35]. The high
mortality of variceal haemorrhage in patients with CF [24]
justifies screening and prophylactic banding of carefully selected
patients by experienced endoscopists.
We evaluated whether splenomegaly or thrombocytopaenia
(or both) could predict the presence of large oesophageal varices
at endoscopy, in order to obviate the need for further endoscopy
in patients with CF; this is an effective strategy for cirrhosis of
other causes [31–34]. There was no correlation between spleensize and the endoscopic presence of varices. Splenomegaly was
found in all but one patient with cirrhosis but also in nine
patients with no clinical or US evidence of liver disease as
reported previously [12]. The cause of splenomegaly without
varices is unexplained but may reflect chronic sepsis. The
platelet count was also unrelated to the presence of varices.
Most patients with cirrhosis are also screened routinely for
the presence of HCC, which has been reported only twice in the
context of CF-related liver disease [27,36]. There are insuffi-
cient data to indicate whether adults with CF-related liver
disease should be screened for HCC; the fact that cystic fibrosis
is associated with other malignancies [37] might suggest that
surveillance with regular ultrasound and alpha-feto protein
would be advisable until the role for screening is clearer.
In conclusion, liver abnormalities are frequent in adults with
CF. Patients remain stable and there does not seem to be an
increased requirement for liver transplantation in the adult
population. The reason for the apparent stability of this group is
unknown; possible explanations include focused care through a
multidisciplinary specialist clinic, prevention of progression by
UDCA or that “screening” for liver disease merely detects those
adults with a milder phenotype who do not develop sympto-
matic or progressive liver disease.References[1] Wood RM, Boat TF, Doershuk CF. Cystic fibrosis. Am Rev Respir Dis
1976;113:833–78.
[2] Geddes DM. Cystic fibrosis. Future trends in care. Thorax 1988;43:115–30.
[3] Fitzsimmons SC. The changing epidemiology of cystic fibrosis. J Paediatr
1993;122:1–9.
[4] NarkewiczMR.Markers of cystic fibrosis-associated liver disease. J Paediatr
Gastroenterol Nutr 2001;32:421–2.
[5] Cystic Fibrosis Foundation. Patient Registry 2000 Annual Report.
Bethesda, MD: Cystic fibrosis Foundation; 2001.
[6] Feranchak AP, Sokol RJ. Cholangiocyte biology and cystic fibrosis liver
disease. Semin Liver Dis 2001;21:471–88.
[7] Colombo C, Battezzati PM, Podda M. Hepatobiliary disease in cystic
fibrosis. Semin Liver Dis 1994;14:259–69.
[8] Sidlova K, Skalicka V, Kotaska K, et al. Serum alpha-glutathione S-
transferase as a sensitive marker of hepatocellular damage in patients with
cystic fibrosis. Physiol Res 2003;52:361–5.
[9] Bettinardi N, Felicetta I, Tomasi PA, Colombo C. Carbohydrate 19-9
antigen is not a marker of liver disease in patients with cystic fibrosis. Clin
Chem Lab Med 2003;41:311–6.
[10] Wyatt HA, Dharwan A, Cheeseman P, Mieli-Vergani G, Price JF. Serum
hyaluronic acid concentrations are increased in cystic fibrosis patients with
liver disease. Arch Dis Child 2002;86:190–3.
[11] Gabolde M, Hubert D, Guilloud-Bataille M, Lenaerts C, Feingold J,
Besmond C. J Med Genet 2001;38:310–1.
[12] Williams SM, Goodman R, Thomson A, McHugh K, Lindsell DRM.
Ultrasound evaluation of liver disease in cystic fibrosis as part of an annual
assessment clinic: a 9 year review. Clinical Radiology 2002;57:365–70.
[13] Williams SG, Evanson JE, Barrett N, Hodson ME, Boultbee JE, Westaby
D. An ultrasound scoring system for the diagnosis of liver disease in cystic
fibrosis. J Hepatol 1995;22:513–21.
[14] Lenaerts C, Lapierre C, Patriquin H, et al. Surveillance for cystic fibrosis-
associated hepatobiliary disease: early ultrasound changes and predispos-
ing factors. J Paediatr 2003;143:343–50.
[15] May GR, Sutherland LR, Shaffer EA. Efficacy of bile acid therapy for
gallstone dissolution: a meta analysis of randomised trials. Aliment
Pharmacol Ther 1993;7:139–48.
257K.L. Nash et al. / Journal of Cystic Fibrosis 7 (2008) 252–257[16] Poupon R, Balkau B, Eschwege E, Poupon R, UDCA-PBC Study Group.
A multicentre, controlled trial of ursodiol for the treatment of primary
biliary cirrhosis. N Engl J Med 1991;324:1548–54.
[17] Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of
the effect of ursodeoxycholic acid on urinary bile acid excretion and liver
morphology in cystic-fibrosis-associated liver disease. Hepatology
1998;27:166–74.
[18] Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A, Italian
Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a
double-blind multicentre trial. Hepatology 1996;23:1484–90.
[19] Cheng K, Ashby D, Smyth R. Ursodeoxycholic acid for cystic fibrosis-
related liver disease. Cochrane Database Syst Rev 2000:CD000222.
[20] Nousia-Arvanitakis S, Fotoulaki M, Economou H, Xefteri M, Galli-
Tsinopoulou A. Long-term prospective study of the effect of ursodeoxy-
cholic acid on cystic fibrosis-related liver disease. J Clin Gastroenterol
2001;32:324–8.
[21] Colombo C, Battezzatti PM, Crosignani A, et al. Liver disease in cystic
fibrosis: a prospective study on incidence, risk factors, and outcome.
Hepatology 2002;36:1374–82.
[22] Lamireau T, Monnereau S, Martin S, Marcotte J, Winnock M, Alvarez F.
Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J
Hepatol 2004;41:920–5.
[23] Lindbauld A, Glaumann H, Strandvik B. Natural history of liver disease in
cystic fibrosis. Hepatology 1999;30:1151–8.
[24] Noble-Jamieson G, Barnes N, Jamieson N, Friend P, Calne R. Liver
transplantation for hepatic cirrhosis in cystic fibrosis. J R SocMed 1996;89
(Suppl 27):31–7.
[25] Nash KL, Collier JD, French J et al. Cystic fibrosis liver disease: To
transplant or not to transplant? American Journal of Transplantation 2007;
Oct. 31 (EPub).
[26] Milkiewicz P, Skiba G, Kelly D, et al. Transplantation for cystic fibrosis:
Outcome following early liver transplantation. J Gastroenterol Hepatol
2002;17:208–13.[27] McKeon D, Day A, Parmar J, Alexander G, Bilton D. Hepatocellular
carcinoma in association with cirrhosis in a patient with cystic fibrosis.
J Cyst Fibros 2004;3:193–5.
[28] Colombo C, Battezzati PM, Strazzabosco M, Podda M. Hepatobiliary
problems in cystic fibrosis. Semin Liver Dis 1998;18:227.
[29] Fiegelson J, Anastopoulous C, Poquet M, Pecau Y, Munck A, Navarro J.
Liver cirrhosis in cystic fibrosis-therapeutic implications and long-term
follow up. Arch Dis Child 1993;68:653–7.
[30] Fagundes ED, Silva RA, Roguete ML, et al. Validation of the Williams
ultrasound scoring system for the diagnosis of liver disease in cystic
fibrosis. J Paediatr (Rio J) 2004;80:380–6.
[31] Bressler B, Pinto R, El-Ashry D, Heathcote EJ. Which patients with primary
biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic
screening for oesophageal varices detection? Gut 2005;54:407–10.
[32] Schepsis F, Camma C, Niceforo D, et al. Which patients with cirrhosis
should undergo screening for oesophageal varices detection? Hepatology
2001;33:333–8.
[33] Chalasami N, Imperiale TF, Ismail A, et al. Predictors of large oesophageal
varices in patients with cirrhosis. Am J Gastroenterol 1999;94:3285–91.
[34] Thomopoulos KC, Labropoulou-Karatza C, Mimidis KP, Katsakoulis EC,
Iconomou G, Nikolopoulou VN. Non-invasive predictors of the presence
of large oesophageal varices in patients with cirrhosis. Dig Liver Dis
2003;35:473–8.
[35] Balfour-Lynn IM, Elbourn JS. “CF asthma”: what it is and what do we do
about it? Thorax 2002;57:742–8.
[36] Kelleher T, Staunton M, O’Mahony S, McCormick PA. Advanced
hepatocellular carcinoma associated with cystic fibrosis. Eur J Gastro-
enterol Hepatol 2005;17:1123–4.
[37] Agrons GA, Corse WR, Markowitz RI, Suarez ES, Perry DR.
Gastrointestinal manifestations of cystic fibrosis: radiologic-pathologic
correlation. Radiographics 1996;16:871–93.
